Research programme: monoclonal antibody therapeutics - sanofi pasteur/Valneva

Drug Profile

Research programme: monoclonal antibody therapeutics - sanofi pasteur/Valneva

Alternative Names: monoclonal antibodies; monoclonal antibodies - sanofi pastuer/Vivalis

Latest Information Update: 03 Mar 2014

Price : $50

At a glance

  • Originator sanofi pasteur; Vivalis
  • Developer Sanofi Pasteur; Valneva
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Bacterial infections; Viral infections

Most Recent Events

  • 25 Feb 2014 Research is ongoing in France
  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 26 Apr 2012 Monoclonal antibodies are still in early research stages for infectious diseases in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top